Skip to search formSkip to main contentSkip to account menu

aplaviroc

Known as: 4-(4-{[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undecan-9-yl]methyl}phenoxy)benzoic acid, benzoic acid, 4-(4-(((3R)-1-butyl-3-((R)-cyclohexylhydroxymethyl)-2,5-dioxo-1,4,9- triazaspiro(55)undec-9-yl)methyl)phenoxy)- 
A C-C Chemokine Receptor Type 5 (CCR5) antagonist with activity against HIV-1. Aplaviroc inhibits HIV-1 entry via CCR5 coreceptor interaction.
National Institutes of Health

Related topics

Related topics

6 relations
AK602Aplaviroc Hydrochloride

Broader (3)

BenzoatesPiperazinesSpiro Compounds

Narrower (1)

GW873140

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Gating function of isoleucine‐116 in TM‐3 (position III:16/3.40) for the activity state of the CC‐chemokine receptor 5 (CCR5)
A conserved amino acid within a protein family indicates a significance of the residue. In the centre of transmembrane helix (TM… 
2013
2013
Antibody Conjugation Approach Enhances Breadth and Potency of Neutralization of Anti-HIV-1 Antibodies and CD4-IgG
ABSTRACT Broadly neutralizing antibodies PG9 and PG16 effectively neutralize 70 to 80% of circulating HIV-1 isolates. In this… 
2011
2011
Theoretical Studies on the Interactions and Interferences of HIV-1 Glycoprotein gp120 and Its Coreceptor CCR5
The interaction between the HIV gp120 protein and coreceptor CCR5 or CXCR4 of the host cell is critical in mediating the HIV… 
2010
2010
Potent Inhibition of HIV‐1 Entry with a Chemically Programmed Antibody Aided by an Efficient Organocatalytic Synthesis
Innovative new approaches to HIV-1 prophylaxis and therapy are desperately needed. Despite the successes of highly active… 
2009
2009
Antiviral activity and safety of aplaviroc, a CCR5 antagonist, in combination with lopinavir/ritonavir in HIV‐infected, therapy‐naïve patients: results of the EPIC study (CCR100136) *
This phase IIb study explored the antiviral activity and safety of the investigational CC chemokine receptor 5 (CCR5) antagonist… 
2008
2008
Virologic Failure in First-Line Human Immunodeficiency Virus Therapy with a CCR5 Entry Inhibitor, Aplaviroc, plus a Fixed-Dose Combination of Lamivudine-Zidovudine: Nucleoside Reverse Transcriptase…
ABSTRACT The CCR102881 (ASCENT) study evaluated the antiviral activity of the novel CCR5 entry inhibitor aplaviroc plus a fixed… 
2008
2008
Formulation development and process scale up of a high shear wet granulation formulation containing a poorly wettable drug.
Aplaviroc 200 mg tablets were made by a high shear wet granulation process. A formulation and process DOE were carried out to… 
2008
2008
[CCR5 antagonists: a new class of antiretrovirals].
2006
2006
The effects of ritonavir and lopinavir/ritonavir on the pharmacokinetics of a novel CCR5 antagonist, aplaviroc, in healthy subjects.
AIMS This study assessed the effects of the CYP3A inhibitors lopinavir/ritonavir (LPV/r) on the steady-state pharmacokinetics (PK… 
2005
2005
Trials of aplaviroc halted in treatment-naive patients.
On September 15, 2005, GlaxoSmithKline (GSK) announced that it had halted clinical trials of the CCR5 entry inhibitor, aplaviroc… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)